⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for receptor tyrosine kinase inhibitor

Every month we try and update this database with for receptor tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic CancersNCT01316822
Metastatic Canc...
ARRY-382, cFMS ...
18 Years - Array BioPharma
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic CancersNCT01316822
Metastatic Canc...
ARRY-382, cFMS ...
18 Years - Array BioPharma
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerNCT01496313
Thyroid Cancer
300mg vandetani...
150mg vandetani...
18 Years - Sanofi
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177
Carcinoma, Hepa...
Lenvatinib
Pembrolizumab
Oral Placebo
IV Placebo
TACE
18 Years - Merck Sharp & Dohme LLC
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)NCT04305041
Melanoma
Pembrolizumab
Quavonlimab
Vibostolimab
Lenvatinib
ATRA
18 Years - 120 YearsMerck Sharp & Dohme LLC
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)NCT03713593
Carcinoma, Hepa...
lenvatinib
pembrolizumab
saline placebo
18 Years - Merck Sharp & Dohme LLC
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: